- Home
- SBCF vs IMVT Comparison
SBCF vs IMVT Comparison
Compare SBCF & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBCF
- IMVT
- Stock Information
- Founded
- SBCF 1926
- IMVT 2018
- Country
- SBCF United States
- IMVT United States
- Employees
- SBCF N/A
- IMVT N/A
- Industry
- SBCF Major Banks
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBCF Finance
- IMVT Health Care
- Exchange
- SBCF Nasdaq
- IMVT Nasdaq
- Market Cap
- SBCF 3.0B
- IMVT 2.7B
- IPO Year
- SBCF N/A
- IMVT N/A
- Fundamental
- Price
- SBCF $31.44
- IMVT $18.98
- Analyst Decision
- SBCF Buy
- IMVT Buy
- Analyst Count
- SBCF 4
- IMVT 9
- Target Price
- SBCF $29.50
- IMVT $27.71
- AVG Volume (30 Days)
- SBCF 556.9K
- IMVT 1.6M
- Earning Date
- SBCF 10-27-2025
- IMVT 11-07-2025
- Dividend Yield
- SBCF 2.29%
- IMVT N/A
- EPS Growth
- SBCF 19.16
- IMVT N/A
- EPS
- SBCF 1.63
- IMVT N/A
- Revenue
- SBCF $531,697,000.00
- IMVT N/A
- Revenue This Year
- SBCF $28.39
- IMVT N/A
- Revenue Next Year
- SBCF $34.82
- IMVT N/A
- P/E Ratio
- SBCF $19.26
- IMVT N/A
- Revenue Growth
- SBCF 5.40
- IMVT N/A
- 52 Week Low
- SBCF $21.36
- IMVT $12.72
- 52 Week High
- SBCF $32.33
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- SBCF 56.55
- IMVT 65.43
- Support Level
- SBCF $29.83
- IMVT $18.51
- Resistance Level
- SBCF $30.74
- IMVT $19.60
- Average True Range (ATR)
- SBCF 0.98
- IMVT 0.89
- MACD
- SBCF -0.01
- IMVT 0.17
- Stochastic Oscillator
- SBCF 83.14
- IMVT 82.10
About SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.